AnthonyPaulConleyMD

Oncology • Houston, TX

Sarcoma

Associate Professor, Department of Sarcoma Medical Oncology

Join to view full profile

Dr. Conley is on Doximity

As a Doximity member you'll join over two million verified healthcare professionals in a private, secure network.

Gain access to free telehealth tools, such as our “call shielding” and one-way patient texting.
Connect with colleagues in the same hospital or clinic.
Read the latest clinical news, personalized to your specialty.

See Dr. Conley's full profile

Already have an account?

Office
1515 Holcombe Blvd
Unit 450
Houston, TX 77030
Phone+1 713-792-3626

Fax+1 713-794-1934

Education & Training

University of Texas Health Science Center at Houston/M D Anderson Cancer CenterFellowship, Hematology and Medical Oncology, 2007 - 2010
University of Texas Health Science Center at HoustonResidency, Internal Medicine, 2004 - 2007
University of Texas Medical Branch School of MedicineClass of 2004

Certifications & Licensure

FL State Medical License 2010 - Present
TX State Medical License 2007 - 2026
OK State Medical License 2020 - 2021
American Board of Internal Medicine Medical Oncology

Awards, Honors, & Recognition

Young Investigator Award ASCO

Clinical Trials

Basket Study of Entrectinib (RXDX-101) for the Treatment of Patients With Solid Tumors Harboring NTRK 1/2/3 (Trk A/B/C), ROS1, or ALK Gene Rearrangements (Fusions) Start of enrollment: 2015 Nov 19
Active, not recruiting
Phase 2
QUILT-3.031: AMG 337 in Subjects With Advanced or Metastatic Clear Cell Sarcoma Start of enrollment: 2018 Aug 29
Terminated
Phase 2
Testing Atezolizumab Alone or Atezolizumab Plus Bevacizumab in People With Advanced Alveolar Soft Part Sarcoma Start of enrollment: 2017 Apr 25
Active, not recruiting
Phase 2
AG-120 in People With IDH1 Mutant Chondrosarcoma Start of enrollment: 2020 Mar 04
Recruiting
Phase 2
Testing the Combination of Belinostat and SGI-110 (Guadecitabine) or ASTX727 for the Treatment of Unresectable and Metastatic Conventional Chondrosarcoma Start of enrollment: 2020 Sep 08
Active, not recruiting
Phase 2
Cetuximab for the Treatment of Advanced Unresectable or Metastatic Chordoma Start of enrollment: 2022 May 27
Recruiting
Phase 2
Roles: Principal Investigator, Contact
Study of INBRX-109 in Conventional Chondrosarcoma Start of enrollment: 2021 Sep 23
Recruiting
Phase 2
A Study of AdAPT-001 in Subjects With Sarcoma and Refractory Solid Tumors Start of enrollment: 2021 Mar 29
Recruiting
Phase 2
A Study Assessing KB707 for the Treatment of Locally Advanced or Metastatic Solid Tumors Start of enrollment: 2023 Oct 31
Recruiting
Phase 1
A Dose Escalation and Cohort Expansion Study of KB-0742 in Participants With Relapsed or Refractory Solid Tumors or Non-Hodgkin Lymphoma Start of enrollment: 2021 Feb 08
Recruiting
Phase 1, Phase 2
Testing Atezolizumab With or Without Selinexor in Patients >= 18 Years Old With Alveolar Soft Part Sarcoma, the Axiom Study Start of enrollment: 2022 Aug 29
Recruiting
Phase 2
Join now to see all

Publications & Presentations

PubMed

59 citations
Overexpressed PRAME is a potential immunotherapy target in sarcoma subtypes
Jason Roszik, Wei-Lien Wang, John A. Livingston, Christina L. Roland, Vinod Ravi
Clinical Sarcoma Research. 2017-06-15
16 citations
Prognostic factors for uterine adenosarcoma: a review.
Michael J. Nathenson, Anthony P. Conley
Expert Review of Anticancer Therapy. 2018-09-11
21 citations
Patient-reported outcomes from STARTRK-2: a global phase II basket study of entrectinib for ROS1 fusion-positive non-small-cell lung cancer and NTRK fusion-positive so...
Luis Paz-Ares, Fabrice Barlesi, Salvatore Siena, Myung-Ju Ahn, A. Drilon
ESMO Open. 2021-04-27

Journal Articles

Cytokines Produced by Dendritic Cells Administered Intratumorally Correlate with Clinical Outcome in Patients with Diverse Cancers
Ravi Murthy, Robert S Benjamin, Anthony P Conley, Chitra Hosing, David S Hong, Aung Naing, Clinical Cancer Research
Characteristics and Outcomes of Patients with Advanced Sarcoma Enrolled in Early Phase Immunotherapy Trials
David S Hong, Neeta Somaiah, Anthony Conley, Shreyaskumar Patel, Filip Janku, Aung Naing, Kenneth Hess, Robert Benjamin, BioMed Central

Press Mentions

Surviving Sarcoma Took a Different Treatment Route Than I ExpectedJune 26th, 2018
Young Desmoid Tumor Survivor Gets Life Back with 17-Hour SurgeryJune 6th, 2017
MD Anderson Research Highlights for October 4, 2023October 5th, 2023
Join now to see all

Committees

Member, Connective Tissue Oncology Society (CTOS) Outreach Committee 2022 - Present
Member, Institutional Review Board (IRB) 2, MDACC, Houston, TX 2022 - Present
Faculty Senator, Faculty Senate, MDACC, Houston, TX 2021 - Present
Member, Medical Practice Committee, MDACC, Houston, TX 2019 - Present